中国医院用药评价与分析2025，Vol.25Issue(4)：448-452,457,6.DOI:10.14009/j.issn.1672-2124.2025.04.015
参附养心汤用于慢性心力衰竭的有效性和安全性的Meta分析
Meta-Analysis on Efficacy and Safety of Shenfu Yangxin Decoction in the Treatment of Chronic Heart Failure
摘要
Abstract
OBJECTIVE:To systematically evaluate the efficacy and safety of Shenfu Yangxin decoction in the treatment of chronic heart failure(CHF).METHODS:Seven databases including CNKI,VIP,Wanfang Data,SinoMed,PubMed,the Cochrane Library,and Embase were retrieved to collect randomized controlled trials(RCT)of Shenfu Yangxin decoction in the treatment of CHF(the control group was treated with conventional Western medicine,while the observation group used ginseng Yangxin soup alone or used Shenfu Yangxin decoction together on the basis of the control group)up to Nov.2024.The quality of the literature was evaluated according to the Cochrane standards,the data were systematically reviewed by using RevMan 5.4 and Stata/MP 18 software,and the quality of evidence was assessed according to GRADE criteria.RESULTS:A total of 13 RCT were enrolled,including 1 232 patients.Meta-analysis showed that the total clinical effective rate of observation group was higher than that in control group,the difference was statistically significant(RR=1.23,95%CI=1.16-1.30,P<0.000 01).The observation group was superior to the control group in improving left ventricular ejection fraction(LVEF),calcitonin gene-related peptide(CGRP),and reducing left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),tumor necrosis factor α(TNF-α),and endothelin(ET)levels.The evidence was not sufficient to prove that there was statistically significant difference in the incidence of adverse drug reactions between two groups(RR=1.05,95%CI=0.49-2.25,P=0.89).GRADE system evaluation showed that the overall clinical efficacy,CGRP,and ET were evaluated as moderate quality evidence,LVESD and TNF-α were evaluated as low quality evidence,and LVEF and LVEDD were evaluated as very low quality evidence.CONCLUSIONS:Based on the results,Shenfu Yangxin decoction can improve the total effective rate of CHF patients,improve the level of cardiac function,vascular endothelial function and inflammatory response indicators,without increasing the risk of adverse drug reactions.关键词
参附养心汤/慢性心力衰竭/随机对照试验/Meta分析Key words
Shenfu Yangxin decoction/Chronic heart failure/Randomized controlled trials/Meta-analysis分类
药学引用本文复制引用
王慧琳,卫军营..参附养心汤用于慢性心力衰竭的有效性和安全性的Meta分析[J].中国医院用药评价与分析,2025,25(4):448-452,457,6.基金项目
北京市科学技术委员会资助项目(No.Z231100007223009) （No.Z231100007223009）
